BlossomHill Therapeutics, Inc. (BLSM) Reports Preclinical Data on Pan-KRAS BH-501284

BlossomHill Therapeutics presented preclinical data for BH-501284, a non-covalent pan-KRAS inhibitor, showing sustained KRAS pathway suppression and antitumor activity, and said it supports an IND submission planned for Q1 2027.Material DetailsContext by AI AnalystThis is an early-stage R&D update…